Medical Products August 5 Results List: BDX, RMD and more

Quarterly results for medical product companies, which are an integral part of the broader medical industry, are expected to have seen improved business growth in the reportable quarter compared to the dismal performance affected by COVID-19 in the quarter of the previous year.

There was a decline in the number of COVID-19 cases in the United States and other developed markets throughout the second quarter due to the acceleration of the vaccination process. This, in turn, has led to a substantial rebound in core sales volumes. The easing of restrictions has helped non-COVID and elective legacy businesses of those businesses recover.

Apart from that, the second quarter results of industry participants are likely to reflect substantial market adoption of healthcare support products and services related to COVID-19. In reality, AbbottABT’s underlying legacy diagnostic business continued to improve in the second quarter, driven by improved levels of routine diagnostic testing and continued deployment of Alinity platforms.

Meanwhile, even as vaccine and therapeutic manufacturers have benefited from the significant market adoption of their COVID-19 healthcare support products and services, demand for COVID-19 testing has grown. slowed down (due to mass vaccination).

The medical sector has achieved encouraging quarterly performance so far this reporting cycle. According to the latest profit forecast, second-quarter profits for this sector are expected to improve 23.2% on revenue growth of 18.4%.

Let’s take a look at five medical product stocks that are expected to report results on August 5.

Becton, Dickinson and company BDX: Becton, Dickinson and Company, commonly known as BD, will likely have demonstrated substantial strength in its life sciences segment in the third quarter of fiscal 2021 results. numerous regulatory approvals for its products. For example, in May, the company announced that the industry’s first self-collection statement for human papillomavirus (“HPV”) screening had been CE marked. This is likely to have contributed to the life sciences segment, thereby generating income. (Read more: BD Gears Up for Q3 Results: What’s Next?)

Our proven model does not predict higher profits for BD this time around. The combination of a positive earnings ESP and a Zacks # 1 (strong buy), 2 (buy), or 3 (hold) ranking increases the odds of beating the winnings. You can discover the best stocks to buy or sell before they are flagged with our ESP Earnings Filter.

The company has a Zacks # 3 rank and an ESP on earnings of -0.69%.

You can see The full list of today’s Zacks # 1 Rank stocks here.

Becton, Dickinson and Company Prize and EPS surprise

Becton, Dickinson and Company price-eps-surprise | Quote Becton, Dickinson and company

ResMed Inc. RMD: The resumption of core patient flow and the growing adoption of digital health solutions and other tools to facilitate remote care amid the pandemic likely contributed to ResMed’s fiscal performance in Q4 2021. Strong organic growth rates in the US pharmaceutical market, population demographics and improved patient access to medical care could be reflected in the quarterly results to be released. The company saw strong sales in its mask product portfolio in the United States, Canada and Latin America in the fiscal third quarter and momentum is also expected to continue in the quarter to be released.

ResMed has a Zacks Rank 2 and Earnings ESP of -0.60%.

ResMed Inc. Price and BPA Surprise

ResMed Inc. Price and BPA Surprise

ResMed Inc. price-eps-surprise | Quote ResMed Inc.

Cardinal Health, Inc. CAH: Cardinal Health’s pharmaceutical segment is the second largest pharmaceutical distributor in the United States. Elective procedures and doctor visits are expected to return to pre-COVID 19 levels by the end of fiscal 2021, with greater impact in the first half of the year. This could be reflected in the segment results in the fourth quarter 2021 results. Cardinal Health’s medical unit may have contributed significantly to the overall fourth quarter fiscal performance. This segment’s revenue is expected to reflect increased sales of personal protective equipment (PPE) and increased volumes in its laboratory business. (Read More: Cardinal Health To Release Fourth Quarter Results: What’s In Store?)

Cardinal Health has a rank 3 of Zacks and a revenue ESP of -0.28%.

Cardinal Health, Inc. Awards and EPS Surprise

Cardinal Health, Inc. Price and EPS Surprise

Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote

Abiomed inc. ABMD: The strong momentum of the Impella product line, which was seen in the fourth quarter of fiscal 2021, is also expected to continue through the first quarter of fiscal 2022, thanks to continued strong customer adoption . Abiomed’s revenue in the quarter to be released is expected to reflect the benefits of the sustained momentum of its Impella 5.5 with SmartAssist over the past few months. (Read more: Abiomed to announce Q1 earnings: what’s in the cards?)

Abiomed has a rank 3 of Zacks and an ESP on earnings of 0.00%.

ABIOMED, ​​Inc. Price and EPS Surprise

ABIOMED, ​​Inc.  Price and EPS Surprise

ABIOMED, ​​Inc. price-eps-surprise | ABIOMED Quote, Inc.

DENTSPLY SIRONA Inc. XRAY: DENTSPLY SIRONA’s consumables segment is expected to experience improved revenue in the second quarter of 2021. The rebound in sales of all product categories may have contributed to the increase. Other than that, the continued improvement in sales trends due to reopening of dental offices and increased patient visits may have helped the business performance in the quarter to be released. (Read More: DENTSPLY SIRONA To Release Second Quarter Results: What’s In Store?)

DENTSPLY SIRONA has a Zacks Rank # 2 and an ESP of + 6.77%.

DENTSPLY SIRONA Inc. Prizes and EPS Surprise

DENTSPLY SIRONA Inc. Prizes and EPS Surprise

DENTSPLY SIRONA Inc. price-eps-surprise | Quote DENTSPLY SIRONA Inc.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is expected to exceed $ 775 billion by 2024 as scientists develop treatments for thousands of diseases. They are also finding ways to modify the human genome to literally erase our vulnerability to these diseases.

Zacks just released Century of Biology: 7 Biotech Stocks to Buy Now to help investors profit from 7 stocks that are on the verge of outperforming. Our recent biotech recommendations have produced gains of + 50%, + 83% and + 164% in as little as 2 months. The actions in this report could perform even better.

See these 7 revolutionary actions now >>

Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Cardinal Health, Inc. (CAH): Free Inventory Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

ABIOMED, ​​Inc. (ABMD): Free Stock Analysis Report

To read this article on, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Leave a Reply

Your email address will not be published.